Ascletis raises $100M in series B

Ascletis BioScience Co. Ltd. (Hangzhou, China) raised $100 million in a series B round led by C-Bridge Capital. New investors QianHai Equity Investment, Focus Media Jiangnanchun Foundation and WTT Investment also participated, as did existing investors Goldman Sachs and Tasly Pharmaceutical Co. Ltd. (Shanghai:600535).

Ascletis hopes that this year, it can become the first Chinese company to launch an innovative HCV treatment in China. Last week, Ascletis said China FDA accepted for review an NDA for danoprevir (ASC08) to treat HCV infection. The company holds Chinese rights to the HCV NS3/4A protease inhibitor from Roche (SIX:ROG; OTCQX:RHHBY) (see BioCentury Extra, Dec. 30, 2016)...